628. Pharmacokinetics, Safety and Tolerability of Co-administration of Nacubactam and β-lactams after Multiple Doses in Japanese Healthy Subjects

BACKGROUND: Increase of carbapenem-resistant Enterobacterales (CRE) is a serious problem in the clinical setting and drugs which can treat patients with CRE are still limited. Nacubactam (OP0595) is a novel diazabicyclooctane-type β-lactamase inhibitor and being developed as a standalone drug to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Hiroki, Morita, Jun, Miura, Tatsuo, Sumiya, Masayo, Takaya, Risako, Kondo, Kenichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644807/
http://dx.doi.org/10.1093/ofid/ofab466.826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644807/
http://dx.doi.org/10.1093/ofid/ofab466.826

Ejemplares similares